

# Andrea Harrer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1301245/publications.pdf>

Version: 2024-02-01

46  
papers

853  
citations

430442

18  
h-index

500791

28  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1435  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumefactive MS lesions under fingolimod. <i>Neurology</i> , 2013, 81, 1654-1658.	1.5	72
2	Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1209-1212.	1.4	69
3	Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. <i>Drug Discovery Today</i> , 2012, 17, 296-309.	3.2	59
4	Reshaping the Bet v 1 fold modulates TH polarization. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1571-1578.e9.	1.5	53
5	Diclofenac Hypersensitivity: Antibody Responses to the Parent Drug and Relevant Metabolites. <i>PLoS ONE</i> , 2010, 5, e13707.	1.1	48
6	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a Germanâ€“Austrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	1.8	46
7	Isoform identification and characterization of Art v 3, the lipid-transfer protein of mugwort pollen. <i>Molecular Immunology</i> , 2009, 46, 1919-1924.	1.0	42
8	Characterization of plant food allergens: An overview on physicochemical and immunological techniques. <i>Molecular Nutrition and Food Research</i> , 2010, 54, 93-112.	1.5	35
9	Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2013, 173, 381-389.	1.1	32
10	Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. <i>Multiple Sclerosis Journal</i> , 2011, 17, 16-23.	1.4	30
11	Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. <i>Journal of Neuroimmunology</i> , 2011, 234, 148-154.	1.1	29
12	Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 221-227.	1.8	28
13	Molecular characterization of Api g 2, a novel allergenic member of the lipidâ€“transfer protein 1 family from celery stalks. <i>Molecular Nutrition and Food Research</i> , 2011, 55, 568-577.	1.5	26
14	Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. <i>Drug Discovery Today</i> , 2012, 17, 671-684.	3.2	25
15	Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactionsâ€“Potential and Limitations. <i>Frontiers in Pharmacology</i> , 2016, 7, 171.	1.6	21
16	High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2015, 180, 383-392.	1.1	19
17	Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumabâ€“A Flow Cytometric Study on Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e31784.	1.1	18
18	Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?. <i>Acta Neurologica Scandinavica</i> , 2014, 129, e12-e15.	1.0	18

#	ARTICLE	IF	CITATIONS
19	The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune Functions. <i>BioMed Research International</i> , 2016, 2016, 1-16.	0.9	15
20	Cerebrospinal fluid CXCL13 indicates disease course in neuroinfection: an observational study. <i>Journal of Neuroinflammation</i> , 2019, 16, 13.	3.1	14
21	Chemokine CXCL13 in serum, CSF and blood – CSF barrier function: evidence of compartment restriction. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 7.	2.4	14
22	Human Cerebrospinal Fluid Promotes Neuronal Viability and Activity of Hippocampal Neuronal Circuits In Vitro. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 54.	1.8	13
23	Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies. <i>Multiple Sclerosis Journal</i> , 2012, 18, 506-509.	1.4	12
24	The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 40.	2.4	12
25	Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	11
26	Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103560.	0.9	11
27	Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod. <i>International Journal of Molecular Sciences</i> , 2015, 16, 21832-21845.	1.8	10
28	Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. <i>Drug Discovery Today</i> , 2011, 16, 8-21.	3.2	9
29	Beyond LNB: Real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases. <i>Journal of Neuroimmunology</i> , 2020, 338, 577087.	1.1	9
30	Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study. <i>Journal of Clinical Virology</i> , 2020, 127, 104340.	1.6	9
31	CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. <i>Oncotarget</i> , 2016, 7, 49459-49469.	0.8	8
32	Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy. <i>Acta Neurologica Scandinavica</i> , 2012, 126, e11-e16.	1.0	6
33	From natalizumab to fingolimod in eight weeks – Immunological, clinical, and radiological data in quest of the optimal switch. <i>Clinical Immunology</i> , 2017, 176, 87-93.	1.4	6
34	Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102727.	0.9	5
35	Elevated Toll-Like Receptor-Induced CXCL8 Secretion in Human Blood Basophils from Allergic Donors Is Independent of Toll-Like Receptor Expression Levels. <i>PLoS ONE</i> , 2016, 11, e0149275.	1.1	5
36	Role and Relevance of Cerebrospinal Fluid Cells in Diagnostics and Research: State-of-the-Art and Underutilized Opportunities. <i>Diagnostics</i> , 2022, 12, 79.	1.3	4

#	ARTICLE	IF	CITATIONS
37	High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) – A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 220-226.	0.9	3
38	Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab. <i>British Journal of Dermatology</i> , 2020, 183, 404-404.	1.4	3
39	TaqManR Proximity ligation technology for the detection of heterodimeric adhesion receptors on lymphocytes. <i>Journal of Immunological Methods</i> , 2014, 404, 81-86.	0.6	2
40	Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukoencephalopathy with an excellent outcome. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 172-174.	0.5	1
41	Therapeutisches Drug-Monitoring der Natalizumab-Sättigung von Immunzellen mittels Durchflusszytometrie bei Multipler Sklerose/Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.1	0
42	Zukünftiger Stellenwert von Liquor-Biomarker in der modernen MS-Therapie/Future relevance of CSF biomarkers in modern MS treatment. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.1	0
43	Überblick über Labormethoden zur Überwachung innovativer Therapieregimes bei Multipler Sklerose/Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.1	0
44	Flow cytometry and drug-monitoring of natalizumab saturation of immune cells in multiple	0.1	0
45	A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with a reduced therapeutic effectiveness of natalizumab. <i>Laboratoriums Medizin</i> , 2015, 38, .	0.1	0
46	Routine-taugliche durchflusszytometrische Methode zur Identifikation von Multiple Sklerose PatientInnen mit einer nicht ausreichenden Therapieeffizienz unter einer Natalizumab-Therapie. <i>Laboratoriums Medizin</i> , 2014, 38, .	0.1	0